Trials / Conditions / Non-valvular Atrial Fibrillation (NVAF)

Non-valvular Atrial Fibrillation (NVAF)

15 registered clinical trials studyying Non-valvular Atrial Fibrillation (NVAF) — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Prospective, Single-arm Study Evaluating the Endothelialization Effect and Timeline of AnchorMan® Left Atria NCT07396493	Shanghai Zhongshan Hospital	N/A
Active Not Recruiting	FIM Study of the LAmbre™ II LAA Occluder in Non-Valvular AF Patients NCT07385599	Lifetech Scientific (Shenzhen) Co., Ltd.	N/A
Active Not Recruiting	To Compare the Pharmacokinetics and Safety After a Single Dose Administration of IN-G00002 and IN-R00002 in He NCT06725355	HK inno.N Corporation	Phase 1
Completed	The Safety and Effectiveness of Warfarin Vs Apixaban in Patients With NVAF/ VTE and ESKD on Dialysis NCT06606275	Abu Dhabi Health Services Company	—
Completed	A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients Wit NCT05022758	Bayer	—
Completed	A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagul NCT05027061	Bristol-Myers Squibb	—
Recruiting	A Study Evaluating the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian NCT05232643	Bristol-Myers Squibb	—
Completed	Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in NCT04356989	Bayer	—
Completed	A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemi NCT03887780	Bayer	—
Completed	Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients NCT03746301	Bayer	—
Unknown	Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPT NCT03234114	The First Affiliated Hospital with Nanjing Medical University	Phase 4
Completed	AMPLATZER™ Cardiac Plug Observational Post-Approval Study NCT02954237	Abbott Medical Devices	—
Completed	Factor XA - Inhibition in RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry NCT02663076	GWT-TUD GmbH	—
Withdrawn	Early Post-marketing Study of Eliquis (Apixaban) NCT02153424	Bristol-Myers Squibb	—
Completed	Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan NCT01598051	Bayer	—